Sutro Biopharma, Inc. (STRO) earnings
Quarterly results of Sutro Biopharma, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.
Next earnings date
Sutro Biopharma, Inc. was expected to report around November 5, 2026; nothing is on file with the SEC yet.
Latest quarter: Q2 FY2026
In Q2 FY2026 (ended June 30, 2026) Sutro Biopharma, Inc. reported revenue of $9.8M (-84.6% on the same quarter a year earlier) and a net loss of $38.5M.
Diluted earnings per share were -$2.33.
Quarter by quarter
| Quarter | Revenue | vs year ago | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | $9.8M | -84.6% | -$38.5M | -$2.33 |
| Q1 FY2026 | $14.5M | -16.5% | -$38.5M | -$2.94 |
| Q4 FY2025 | $11.6M | -21.4% | -$46.8M | - |
| Q3 FY2025 | $9.7M | +13.8% | -$56.9M | -$0.67 |
| Q2 FY2025 | $63.7M | - | -$11.5M | -$1.35 |
| Q1 FY2025 | $17.4M | - | -$76M | -$9.08 |
| Q4 FY2024 | $14.8M | - | -$72.4M | - |
| Q3 FY2024 | $8.5M | - | -$48.8M | -$0.59 |
Results filings
- Quarterly report 10-Q
- Quarterly results 8-K
- Quarterly report 10-Q
- Quarterly results 8-K
When is Sutro Biopharma, Inc.'s next earnings date?
Sutro Biopharma, Inc. was expected to report around November 5, 2026; nothing is on file with the SEC yet.
What were Sutro Biopharma, Inc.'s latest quarterly results?
For Q2 FY2026, which ended June 30, 2026, Sutro Biopharma, Inc. reported revenue of $9.8M and a net loss of $38.5M. The figures come from its filing with the SEC.
Is Sutro Biopharma, Inc.'s revenue growing?
Revenue in Q2 FY2026 was $9.8M, down 84.6% from $63.7M in the same quarter a year earlier.
Get an email when STRO reports
Follow STRO and we email you its next results the day they are filed, with the numbers explained.